To The SemiAnnual

1
WELCOME

• To The Semi-Annual
• RTOG
• RA Orientation
• Tampa Florida
• February 1st , 2007

2
RTOG BACKGROUND

• Established in 1968
• Over 250 facilities participate in RTOG trials
• United States
• Canada
• France
• Israel
• Australia
• NCI Funding and Corporate Support

3

• Opened 300 Protocols
• Accrued 60,000 patients to cooperative group
  studies
• Published more than 700 papers
• Maintains a roster of 40 active studies
  devoted to the groups primary disease sites

4
RTOG PRIMARY DISEASE SITES

• CNS
• Head Neck
• Lung
• Breast

5
RTOG PRIMARY DISEASE SITES

• GYN
• Genitourinary
• Bladder
• Prostate
• Gastrointestinal
• Esophagus
• Rectum
• Anal Canal
• Stomach

6
MISSION

• Improve survival outcome and quality of life of
  adults with
• cancer
• Evaluate new forms of radiotherapy delivery.
• brachytherapy, 3-dimensional conformal
  radiotherapy,
• intensity modulated radiotherapy
  (IMRT
• Test new systemic therapies in conjunction with
  RT
• chemotherapy, hormonal treatment, biologic
  agents and
• new classes of cytostatic, cytotoxic and
  targeted therapies
• Employ translational research strategies to
  identify patient
• subgroups at risk for failure with existing
  treatments and
• identify new approaches for these patients

7
RTOG STAFF

• Over 60 RTOG staff members
• Administrative
• Research Associates
• Statisticians
• Quality Assurance
• Protocol Development

8
RECENT ACCOMPLISHMENTS
9
CERVIX CANCER

• RTOG demonstrated that combining chemotherapy
  with pelvic radiation improves the 5 year
  survival rate for women with locally advanced
  cervix cancer from
• 58 to 73.

10
LUNG CANCER

• RTOG FOUND THAT HEALTHIER PATIENTS WITH
  INOPERABLE NON-SMALL-CELL LUNG CANCER HAD BETTER
  RESULTS IF THEY RECEIVED CHEMOTHERAPY DURING
  RADIOTHERAPY RATHER THAN PRIOR TO RADIOTHERAPY.

11
HEAD AND NECK

• RTOG demonstrated the superiority of concomitant
  boost radiotherapy and hyperfractionated
  radiotherapy for locally advanced squamous-cell
  carcinoma.
• RTOG demonstrated that patients who received
  chemotherapy together with their radiotherapy
  after surgery were far less likely to have a
  recurrence of their cancer.

12
BRAIN

• RTOG improved survival more than
• 33
• for patients with a single brain metastasis by
  using whole brain radiotherapy followed by
  stereotactic radiosurgery boost instead of whole
  brain treatment alone.

13
CNS LYMPHOMA

• RTOG improved the median survival for patients
  with non-AIDS-related primary CNS lymphoma from
• 11.6 months to
• 30.4 months
• by giving high dose chemotherapy for 10 weeks
  prior to RT.

14

• THANK YOU !